China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 18 Apr, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Recent Articles
- US Accelerates Access to Therapeutic Psychedelics
- What country would you live in if you can't live in the US?
- Beijing Building Satellite Town for Booming Space Industry
- US Blockade Prompts Iran to Reassert Control over Strait of Hormuz
- China Humanoid Robot Half-Marathon to Showcase Big Advances
- Innocent Indian American Ambushed As a Pedophile by Racist Livestreamer
- $166 Billion in Tariff Refunds to Begin Processing Monday
- Top Kpop Agencies Mull Creating Coachella-Style Global Festival
- Apple's Q1 China iPhone Sales Surged 20%
- Robotic Exoskeleton Helps Elderly Hong Kong Fire Survivors Climb Back for Belongings